Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.clinthera.2020.08.006 http://scihub22266oqcxt.onion/10.1016/j.clinthera.2020.08.006 32883529!7430296!32883529     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Ther 2020 ; 42 (10): 1850-1852 Nephropedia Template TP {{tp|p=32883529|t=2020. Coronavirus 2019, Microthromboses, and Platelet Activating Factor |pdf=|usr=}}{{32883529}} gab.com Text Coronavirus 2019, Microthromboses, and Platelet Activating Factor JO: Clin Ther http://www.kidney.de/pget.php?&tw=1&pmid=32883529 #FOAvip Recent articles have reported elevated markers of coagulation, endothelial injury, and microthromboses in lungs from deceased patients with coronavirus 2019 (COVID-19). Platelets are critical in the formation of thrombi, and their most potent trigger is platelet activating factor (PAF). PAF is produced by cells involved in host defense, and its biological actions bear similarities with COVID-19 disease manifestations, including pulmonary microthromboses and inflammation, possibly via activation of mast cells. The histamine(1) receptor antagonist rupatadine was developed to have anti-PAF activity and inhibits activation of human mast cells in response to PAF. Rupatadine could be repurposed for COVID-19 prophylaxis. Twit Text FOAVip Coronavirus 2019, Microthromboses, and Platelet Activating Factor ????Clin Ther http://www.kidney.de/pget.php?&tw=1&pmid=32883529 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32883529 #FOAvip English Wikipedia <ref>{{Cite pmid|32883529}}</ref> Coronavirus 2019, Microthromboses, and Platelet Activating Factor #MMPMID32883529 Theoharides TC; Antonopoulou S; Demopoulos CA Clin Ther 2020[Oct]; 42 (10): 1850-1852 PMID32883529show ga Recent articles have reported elevated markers of coagulation, endothelial injury, and microthromboses in lungs from deceased patients with coronavirus 2019 (COVID-19). Platelets are critical in the formation of thrombi, and their most potent trigger is platelet activating factor (PAF). PAF is produced by cells involved in host defense, and its biological actions bear similarities with COVID-19 disease manifestations, including pulmonary microthromboses and inflammation, possibly via activation of mast cells. The histamine(1) receptor antagonist rupatadine was developed to have anti-PAF activity and inhibits activation of human mast cells in response to PAF. Rupatadine could be repurposed for COVID-19 prophylaxis. |*Coronavirus Infections/immunology/physiopathology/therapy[MESH] |*Pandemics[MESH] |*Platelet Activating Factor[MESH] |*Pneumonia, Viral/immunology/physiopathology/therapy[MESH] |*Thrombosis[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Humans[MESH] |Inflammation/immunology/physiopathology[MESH] |Mast Cells/immunology[MESH] |Platelet Aggregation/immunology[MESH]Coronavirus 2019, Microthromboses, and Platelet Activating Factor (epmc).pdf DeepDyve Pubget Overpricing